BioDelivery's opioid treatment wins FDA approval
BioDelivery Sciences International Inc said the U.S. Food and Drug Administration had approved its opioid treatment for chronic pain, sending the drugmaker's shares up 23 percent in premarket trading on Monday. Endo International Plc licensed the worldwide manufacturing and marketing rights to the treatment, Belbuca, from BioDelivery in 2012.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063